CDC provides national leadership for HIV prevention research, including the development and evaluation of HIV biomedical and behavioral interventions to prevent HIV transmission and reduce HIV disease progression in the United States and internationally. CDC’s research efforts also include identifying those scientifically proven, cost-effective, and scalable interventions and prevention strategies to be implemented as part of a high-impact prevention approach for maximal impact on the HIV epidemic. Find out more about the Division of HIV/AIDS Prevention’s research.
CDC HIV Related Research
- Pre-Exposure Prophylaxis (PrEP)
- Prevention Benefits of HIV Treatment
- Replicating Effective Programs Plus (REP)
PrEP is short for Pre-Exposure Prophylaxis. It is a new HIV prevention method in which people who do not have HIV take a daily pill to reduce their risk of becoming infected. When used consistently, PrEP has been shown to be effective in men who have sex with men and heterosexually active men and women.
The advent in 1996 of potent combination antiretroviral therapy (ART), sometimes called HAART (highly active antiretroviral therapy) or cART (effective combination antiretroviral therapy), changed the course of the HIV epidemic.
The programs in REP are tested, science-based behavioral interventions with demonstrated evidence of effectiveness in reducing risky behaviors, such as unprotected sex, or in encouraging safer ones, such as using condoms and other methods of practicing safer sex.
Evidence-based interventions (EBIs) are identified through an ongoing systematic review effort and listed in the Compendium of Evidence-based Interventions. These EBIs are the strongest interventions in the scientific literature to date that have been rigorously evaluated and have demonstrated evidence of efficacy.